Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial
Neil Fleshner(Princess Margaret Cancer Centre), Roger S. Rittmaster(Research Triangle Park Foundation), Matthew C. Somerville(PAREXEL International (United States)), Michael S. Cookson(University of Oklahoma Health Sciences Center), Samir S. Taneja(NYU Langone Health), Leonard G. Gomella(Thomas Jefferson University), M. Scott Lucia(University of Colorado Anschutz Medical Campus), Eric Wolford(Research Triangle Park Foundation), Antonio Finelli(University Health Network), Andrew Evans(University of Toronto)
Cited by 68
Related Papers
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845